Send me real-time posts from this site at my email
Zacks

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

Tilray, Inc. TLRY will release financial results for the fourth quarter and fiscal 2021 ended May 31, 2021, before market open on Jul 28.

Let us see how things have shaped up prior to this announcement.

Why a Likely Positive Surprise

Our proven model predicts an earnings beat for Tilray this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Earnings ESP: Earnings ESP for Tilray is +14.47%.

Zacks Rank: It currently carries a Zacks Rank #3.

Factors at Play

Tilray is a leading global cannabis-lifestyle and consumer packaged goods company.

In May 2021, the company completed its previously announced business combination with Aphria. Each Aphria shareholder received 0.8381 of a Tilray share for each Aphria common share held on Apr 30, 2021. The combined company is now one of the leading cannabis-focused consumer packaged goods companies, with the largest global geographic footprint in the industry.

This will be the first quarter of reporting post the merger. Tilray has a strong consumer packaged goods presence in the United States. The combination with Aphria has strengthened its infrastructure with the addition of SweetWater, a leading cannabis lifestyle branded craft brewer. Performance in the quarter under review has likely got a boost with the incremental contribution.

In June 2021, Tilray announced the launch of a new medical cannabis brand, Symbios. Tilray also announced new high-potency, medical cannabis topicals under the Aphria brand designed to target inflammatory joint disease by regulating tissue inflammation when applied topically to the skin.

Revenues have likely shown a recovery as COVID-related lockdowns eased in Canada and Germany.

The new company expects to generate approximately $81 million of annual pre-tax cost synergies within eighteen months and plans to achieve cost synergies in the key areas of cultivation and production, cannabis and product purchasing, sales and marketing, and corporate expenses. Further updates on the same are awaited with the results.

Share Price Performance

Tilray’s stock has surged 61.5% in the year so far against the industry’s decline of 10.1%.


Image Source: Zacks Investment Research

Other Stocks to Consider

Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.

Ironwood Pharmaceuticals Inc. IRWD has an Earnings ESP of +11.11% and a Zacks Rank #2.  You can see the complete list of today’s Zacks #1 Rank stocks here.

AbbVie, Inc. ABBV has an Earnings ESP of +0.86% and a Zacks Rank #3. 

Exact Sciences EXAS has an Earnings ESP of +8.80% and a Zacks Rank #3.


Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Ironwood Pharmaceuticals, Inc. (IRWD): Free Stock Analysis Report
 
AbbVie Inc. (ABBV): Free Stock Analysis Report
 
Exact Sciences Corporation (EXAS): Free Stock Analysis Report
 
Tilray, Inc. (TLRY): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue